SCHEDULE 13G
CUSIP NO. 150934107 PAGE 1 OF 9 PAGES
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)*
Cell Therapeutics, Inc.
(Name of Issuer)
Common Stock, no par value
(Title of Class of Securities)
150934107
(CUSIP Number)
December 31, 2006
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
| | Rule 13d-1(b)
|X| Rule 13d-1(c)
| | Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 2 OF 9 PAGES
- ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Alexandra Global Master Fund Ltd.
98-0448776
- ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)| |
(B)| | (See Item 6)
- ------------------------------------------------------------------------- -
3 SEC USE ONLY
- ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
- ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 1,065,036 shares of Common Stock (See Item 4)
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
1,065,036 shares of Common Stock (See Item 4)
- ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,065,036 shares of Common Stock (See Item 4)
- ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) | |
- ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.7% (See Item 4)
- ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- ------------------------------------------------------------------------- -
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 3 OF 9 PAGES
- ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Alexandra Investment Management, LLC
13-4092583
- ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)| |
(B)| | (See Item 6)
- ------------------------------------------------------------------------- -
3 SEC USE ONLY
- ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 1,065,036 shares of Common Stock (See Item 4)
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
1,065,036 shares of Common Stock (See Item 4)
- ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,065,036 shares of Common Stock (See Item 4)
- ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) | |
- ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.7% (See Item 4)
- ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
OO
- ------------------------------------------------------------------------- -
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 4 OF 9 PAGES
- ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Mikhail A. Filimonov
- ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)| |
(B)| | (See Item 6)
- ------------------------------------------------------------------------- -
3 SEC USE ONLY
- ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.
- ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 1,065,036 shares of Common Stock (See Item 4)
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
1,065,036 shares of Common Stock (See Item 4)
- ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,065,036 shares of Common Stock (See Item 4)
- ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) | |
- ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.7% (See Item 4)
- ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
- ------------------------------------------------------------------------- -
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 5 OF 9 PAGES
Item 1(a). Name of Issuer:
Cell Therapeutics, Inc., a Washington corporation (the
"Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
501 Elliott Avenue West, Suite 400
Seattle, Washington 98119
Item 2(a). Names of Persons Filing:
Alexandra Global Master Fund Ltd. ("Alexandra")
Alexandra Investment Management, LLC ("Management")
Mikhail A. Filimonov ("Filimonov")
Item 2(b). Address of Principal Business Office:
Alexandra - Citco Building, Wickams Cay, P.O. Box 662,
Road Town, Tortola, British Virgin Islands
Management - 767 Third Avenue, 39th Floor, New York,
New York 10017
Filimonov - 767 Third Avenue, 39th Floor, New York,
New York 10017
Item 2(c). Place of Organization or Citizenship:
Alexandra - British Virgin Islands
Management - Delaware
Filimonov - U.S.
Item 2(d). Title of Class of Securities:
Common Stock, no par value per share, of the Issuer (the
"Common Stock")
Item 2(e). CUSIP Number: 150934107
Item 3. This Schedule is filed pursuant to Rule 13d-1(c) by
Alexandra, Management and Filimonov
Item 4. Ownership:
(a) Amount Beneficially Owned:
Alexandra: 1,065,036 shares*
Management: 1,065,036 shares*
Filimonov: 1,065,036 shares*
(b) Percent of Class:
Alexandra: 0.7%*
Management: 0.7%*
Filimonov: 0.7%*
(Based on 144,652,751 shares of Common Stock
outstanding, as of October 31, 2006, as reported by
the Issuer in the Issuer's Quarterly Report on Form
10-Q for the quarter ended September 30, 2006)
(c) Number of Shares as to which the Person has:
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 6 OF 9 PAGES
(i) sole power to vote or to direct the vote
-0-
(ii) shared power to vote or to direct the vote:
1,065,036 shares of Common Stock*
(iii) sole power to dispose or to direct the
disposition of
-0-
(iv) shared power to dispose or to direct the
disposition of
1,065,036 shares of Common Stock*
The shares of Common Stock reported as beneficially owned by Alexandra on this
Schedule are 1,065,036 shares of Common Stock that Alexandra has the right to
acquire upon conversion of 6.75% Convertible Senior Notes Due 2010 of the
Issuer.
Management serves as investment advisor to Alexandra. By reason of such
relationship, Management may be deemed to share voting and dispositive power
over the shares of Common Stock owned by Alexandra. Management disclaims
beneficial ownership of the shares of Common Stock listed as beneficially owned
by Alexandra or any other person reporting on this Schedule.
Filimonov serves as the Chairman, the Chief Executive Officer, a Managing Member
and the Chief Investment Officer of Management. By reason of such relationships,
Filimonov may be deemed to share voting and dispositive power over the shares of
Common Stock listed as beneficially owned by Management. Filimonov disclaims
beneficial ownership of the shares of Common Stock listed as beneficially owned
by Management or any other person reporting on this Schedule.
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of
the date hereof each of the Reporting Persons ceased to be the
beneficial owner of more than five percent of the class of
securities, check the following |X|
Item 6. Ownership of More Than Five Percent on Behalf of Another
Person:
Not applicable
Item 7. Identification and Classification of the Subsidiary which
Acquired the Security Being Reported on by the Parent
Holding Company:
Not applicable
Item 8. Identification and Classification of Members of the Group:
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 7 OF 9 PAGES
Not applicable
Item 9. Notice of Dissolution of Group:
Not applicable
Item 10. Certification:
By signing below each signatory certifies that, to the best of its knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
Exhibits:
Exhibit I: Joint Filing Agreement, dated as of February 14, 2007, by and
among Alexandra, Management and Filimonov.
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 8 OF 9 PAGES
SIGNATURE
By signing below each signatory certifies that, to the best of its
knowledge and belief, the securities referred to above were not acquired and are
not held for the purpose of or with the effect of changing or influencing the
control of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that purpose or
effect.
Dated as of February 14, 2007
ALEXANDRA GLOBAL MASTER FUND LTD.
By: ALEXANDRA INVESTMENT MANAGEMENT, LLC,
its Investment Advisor
By: /s/ Mikhail A. Filimonov
----------------------------
Mikhail A. Filimonov
Title: Managing Member
ALEXANDRA INVESTMENT MANAGEMENT, LLC
By: /s/ Mikhail A. Filimonov
----------------------------
Mikhail A. Filimonov
Title: Managing Member
/s/ Mikhail A. Filimonov
----------------------------
Mikhail A. Filimonov
SCHEDULE 13G
CUSIP NO. 150934107 PAGE 9 OF 9 PAGES
Exhibit I
JOINT FILING AGREEMENT
This will confirm the agreement by and among the undersigned that the
Schedule 13G filed with the Securities and Exchange Commission on or about the
date hereof with respect to the beneficial ownership by the undersigned of the
Common Stock, no par value, of Cell Therapeutics, Inc., a Washington
corporation, is being filed, and all amendments thereto will be filed, on behalf
of each of the persons and entities named below in accordance with Rule 13d-1(k)
under the Securities Exchange Act of 1934, as amended. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument.
Dated as of February 14, 2007
ALEXANDRA GLOBAL MASTER FUND LTD.
By: ALEXANDRA INVESTMENT MANAGEMENT, LLC,
its Investment Advisor
By: /s/ Mikhail A. Filimonov
----------------------------
Mikhail A. Filimonov
Title: Managing Member
ALEXANDRA INVESTMENT MANAGEMENT, LLC
By: /s/ Mikhail A. Filimonov
----------------------------
Mikhail A. Filimonov
Title: Managing Member
/s/ Mikhail A. Filimonov
----------------------------
Mikhail A. Filimonov